Search details
1.
Safety and biological outcomes following a phase 1 trial of GD2-specific CAR-T cells in patients with GD2-positive metastatic melanoma and other solid cancers.
J Immunother Cancer
; 12(5)2024 May 15.
Article
in English
| MEDLINE | ID: mdl-38754916
Results
1 -
1
de 1
1
Next >
>>